PMID- 19088040
OWN - NLM
STAT- MEDLINE
DCOM- 20090106
LR  - 20211020
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 14
IP  - 24
DP  - 2008 Dec 15
TI  - The incidence, correlation with tumor-infiltrating inflammation, and prognosis of 
      phosphorylated STAT3 expression in human gliomas.
PG  - 8228-35
LID - 10.1158/1078-0432.CCR-08-1329 [doi]
AB  - PURPOSE: The signal transducer and activator of transcription 3 (STAT3) is 
      frequently overexpressed in most cancers, propagates tumorigenesis, and is a key 
      regulator of immune suppression in cancer patients. We sought to determine the 
      incidence of phosphorylated STAT3 (p-STAT3) expression in malignant gliomas of 
      different pathologic types, whether p-STAT3 expression is a negative prognostic 
      factor, and whether p-STAT3 expression influences the inflammatory response 
      within gliomas. METHODS: Using immunohistochemical analysis, we measured the 
      incidence of p-STAT3 expression in 129 patients with gliomas of various 
      pathologic types in a glioma tissue microarray. We categorized our results 
      according to the total number of p-STAT3-expressing cells within the gliomas and 
      correlated this number with the number of infiltrating T cells and T regulatory 
      cells. We then evaluated the association between p-STAT3 expression and median 
      survival time using univariate and multivariate analyses. RESULTS: We did not 
      detect p-STAT3 expression in normal brain tissues or low-grade astrocytomas. We 
      observed significant differences in the incidence of p-STAT3 expression between 
      the different grades of astrocytomas and different pathologic glioma types. 
      p-STAT3 expression was associated with the population of tumor-infiltrating 
      immune cells but not with that of T regulatory cells. On univariate analysis, we 
      found that p-STAT3 expression within anaplastic astrocytomas was a negative 
      prognostic factor. CONCLUSIONS: p-STAT3 expression is common within gliomas of 
      both the astrocytic and oligodendroglial lineages and portends poor survival in 
      patients with anaplastic astrocytomas. p-STAT3 expression differs significantly 
      between gliomas of different pathologic types and grades and correlated with the 
      degree of immune infiltration.
FAU - Abou-Ghazal, Mohamed
AU  - Abou-Ghazal M
AD  - Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, 
      Houston, Texas 77030, USA.
FAU - Yang, David S
AU  - Yang DS
FAU - Qiao, Wei
AU  - Qiao W
FAU - Reina-Ortiz, Chantal
AU  - Reina-Ortiz C
FAU - Wei, Jun
AU  - Wei J
FAU - Kong, Ling-Yuan
AU  - Kong LY
FAU - Fuller, Gregory N
AU  - Fuller GN
FAU - Hiraoka, Nobuyoshi
AU  - Hiraoka N
FAU - Priebe, Waldemar
AU  - Priebe W
FAU - Sawaya, Raymond
AU  - Sawaya R
FAU - Heimberger, Amy B
AU  - Heimberger AB
LA  - eng
GR  - R01 CA120813/CA/NCI NIH HHS/United States
GR  - R01 CA120813-01A1/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (STAT3 protein, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*chemistry/mortality/pathology
MH  - Child
MH  - Child, Preschool
MH  - Glioma/*chemistry/mortality/pathology
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating/*physiology
MH  - Middle Aged
MH  - Phosphorylation
MH  - Prognosis
MH  - STAT3 Transcription Factor/*analysis
MH  - T-Lymphocytes, Regulatory/*physiology
PMC - PMC2605668
MID - NIHMS78715
EDAT- 2008/12/18 09:00
MHDA- 2009/01/07 09:00
PMCR- 2009/12/15
CRDT- 2008/12/18 09:00
PHST- 2008/12/18 09:00 [entrez]
PHST- 2008/12/18 09:00 [pubmed]
PHST- 2009/01/07 09:00 [medline]
PHST- 2009/12/15 00:00 [pmc-release]
AID - 14/24/8228 [pii]
AID - 10.1158/1078-0432.CCR-08-1329 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2008 Dec 15;14(24):8228-35. doi: 10.1158/1078-0432.CCR-08-1329.